BioCentury reported that Altesa closed a $75 million Series B to advance an antiviral program, with former HHS official Admiral Brett Giroir among the financing backers or leaders named in the coverage. The company said funds will support preclinical and early clinical development for its lead antiviral asset. The financing underscores investor interest in broad‑spectrum and next‑generation antiviral platforms post‑pandemic. BioCentury’s finance report positioned the round alongside other sector moves, including Korsana’s recent raise and follow‑on psilocybin readouts noted in the same briefing. Altesa’s capital infusion should enable IND‑enabling studies and potential Phase 1 starts, shifting program risk toward early human data readouts.